Overexpression of GNAO1 correlates with poor prognosis in patients with gastric cancer and plays a role in gastric cancer cell proliferation and apoptosis

Liu,Zhen; Zhang,Jun; Wu,Lijun; Liu,Jie; Zhang,Mingqing

doi:10.3892/ijmm.2013.1598

Overexpression of GNAO1 correlates with poor prognosis in patients with gastric cancer and plays a role in gastric cancer cell proliferation and apoptosis

Authors:
- Zhen Liu
- Jun Zhang
- Lijun Wu
- Jie Liu
- Mingqing Zhang
View Affiliations

Affiliations: Department of Digestive Diseases, Southeast Hospital, Xiamen University, Zhangzhou, Fujian, P.R. China, Department of Digestive Diseases, Huashan Hospital, Fudan University, Shanghai, P.R. China
Published online on: December 20, 2013 https://doi.org/10.3892/ijmm.2013.1598
Pages: 589-596

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Guanine nucleotide-binding protein (G protein), alpha activating activity polypeptide O (GNAO1) encodes an alpha subunit of the heterotrimeric guanine nucleotide-binding proteins (Gαo), which plays a significant role in the development of various types of cancer, including breast cancer and hepatocellular carcinoma. However, its role in gastric cancer (GC) has not yet been elucidated. In the current study, the expression of Gαo was analyzed by immunohistochemistry in paraffin-embedded tissue sections from 70 patients with GC and its cellular role was examined by small interfering RNA (siRNA)-mediated downregulation. The overexpression of GNAO1 (scores of 2 or 4) was observed in 44 of the 70 patients with GC (62.9%) and the expression of Gαo significantly correlated with the overall survival of the patients with GC after surgery. The median survival rate of patients with a negative or positive expression of Gαo was 61 or 27 months, respectively (P=0.033). The silencing of GNAO1 in GC cells by RNA interference markedly inhibited the proliferation of GC cells and promoted apoptosis by increasing the accumulation of the pro-apoptotic proteins, Puma and Bim, possibly mediated by extracellular signal-regulated kinase 1 and 2 (ERK1/2). This further confirmed the clinical significance of GNAO1, which was overexpressed in GC tissues. To the best of our knowledge, the present study is the first to demonstrate that GNAO1 is overexpressed in GC and that its overexpression correlates with poor prognosis, as it promotes GC cell viability.

View Figures

View References

1	Nakamura T, Nakatsu N, Yoshida Y, et al: Identification of candidate genes determining chemosensitivity to anti-cancer drugs of gastric cancer cell lines. Biol Pharm Bull. 32:1936–1939. 2009. View Article : Google Scholar : PubMed/NCBI
2	Ji YB, Qu ZY and Zou X: Juglone-induced apoptosis in human gastric cancer SGC-7901 cells via the mitochondrial pathway. Exp Toxicol Pathol. 63:69–78. 2011. View Article : Google Scholar : PubMed/NCBI
3	Jackson C, Cunningham D and Oliveira J: Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol. 20(Suppl 4): 34–36. 2009. View Article : Google Scholar : PubMed/NCBI
4	Wang WF, Li J, Du LT, et al: Krüppel-like factor 8 overexpression is correlated with angiogenesis and poor prognosis in gastric cancer. World J Gastroenterol. 19:4309–4315. 2013.
5	Yamada Y, Boku N, Nishina T, et al: Impact of excision repair cross-complementing gene 1 (ERCC1) on the outcomes of patients with advanced gastric cancer: correlative study in Japan Clinical Oncology Group Trial JCOG9912. Ann Oncol. 24:2560–2565. 2013. View Article : Google Scholar
6	Li X, Qi W, Yao R, Tang D and Liang J: Overexpressed transcription factor FOXM1 is a potential diagnostic and adverse prognostic factor in postoperational gastric cancer patients. Clin Transl Oncol. Jul 20–2013.(Epub ahead of print).
7	Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar
8	Neer EJ, Lok JM and Wolf LG: Purification and properties of the inhibitory guanine nucleotide regulatory unit of brain adenylate cyclase. J Biol Chem. 259:14222–14229. 1984.PubMed/NCBI
9	Gierschik P, Milligan G, Pines M, et al: Use of specific antibodies to quantitate the guanine nucleotide-binding protein Go in brain. Proc Natl Acad Sci U S A. 83:2258–2262. 1986. View Article : Google Scholar : PubMed/NCBI
10	Corre I, Baumann H and Hermouet S: Regulation by Gi2 proteins of v-fms-induced proliferation and transformation via Src-kinase and STAT3. Oncogene. 18:6335–6342. 1999. View Article : Google Scholar : PubMed/NCBI
11	Fan X, Brass LF, Poncz M, Spitz F, Maire P and Manning DR: The alpha subunits of Gz and Gi interact with the eyes absent transcription cofactor Eya2, preventing its interaction with the six class of homeodomain-containing proteins. J Biol Chem. 275:32129–32134. 2000. View Article : Google Scholar : PubMed/NCBI
12	Montminy M: Transcriptional regulation by cyclic AMP. Annu Rev Biochem. 66:807–822. 1997. View Article : Google Scholar : PubMed/NCBI
13	Kan Z, Jaiswal BS, Stinson J, et al: Diverse somatic mutation patterns and pathway alterations in human cancers. Nature. 466:869–873. 2010. View Article : Google Scholar : PubMed/NCBI
14	Jia D, Wei L, Guo W, et al: Genome-wide copy number analyses identified novel cancer genes in hepatocellular carcinoma. Hepatology. 54:1227–1236. 2011. View Article : Google Scholar : PubMed/NCBI
15	Garcia-Marcos M, Ghosh P and Farquhar MG: Molecular basis of a novel oncogenic mutation in GNAO1. Oncogene. 30:2691–2696. 2011. View Article : Google Scholar : PubMed/NCBI
16	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
17	Wang XN and Liang H: Some problems in the surgical treatment of gastric cancer. Chin J Cancer. 29:369–373. 2010. View Article : Google Scholar : PubMed/NCBI
18	Nguyen DX, Bos PD and Massagué J: Metastasis: from dissemination to organ-specific colonization. Nat Rev Cancer. 9:274–284. 2009. View Article : Google Scholar : PubMed/NCBI
19	Freeman A, Morris LS, Mills AD, et al: Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res. 5:2121–2132. 1999.PubMed/NCBI
20	Tait SW and Green DR: Mitochondria and cell death: outer membrane permeabilization and beyond. Nat Rev Mol Cell Biol. 11:621–632. 2010. View Article : Google Scholar : PubMed/NCBI
21	Bratton MR, Antoon JW, Duong BN, et al: Gαo potentiates estrogen receptor α activity via the ERK signaling pathway. J Endocrinol. 214:45–54. 2012.
22	Baines CP and Molkentin JD: STRESS signaling pathways that modulate cardiac myocyte apoptosis. J Mol Cell Cardiol. 38:47–62. 2005. View Article : Google Scholar : PubMed/NCBI
23	Fan Y, Chen H, Qiao B, et al: Opposing effects of ERK and p38 MAP kinases on HeLa cell apoptosis induced by dipyrithione. Mol Cells. 23:30–38. 2007.PubMed/NCBI
24	Raman M, Chen W and Cobb MH: Differential regulation and properties of MAPKs. Oncogene. 26:3100–3112. 2007. View Article : Google Scholar : PubMed/NCBI
25	Youle RJ and Strasser A: The BCL-2 protein family: opposing activities that mediate cell death. Nat Rev Mol Cell Biol. 9:47–59. 2008. View Article : Google Scholar : PubMed/NCBI
26	Balmanno K and Cook SJ: Tumour cell survival signalling by the ERK1/2 pathway. Cell Death Differ. 16:368–377. 2009. View Article : Google Scholar : PubMed/NCBI
27	Bean GR, Ganesan YT, Dong Y, et al: PUMA and BIM are required for oncogene inactivation-induced apoptosis. Sci Signal. 6:ra202013.PubMed/NCBI